Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ADVR: BULLS AND BEARS! -- Ignore unavailable to you. Want to Upgrade?

To: BARRY ALLEN who wrote (5940)	5/13/1998 4:20:00 PM
From: Steve D.	Respond to of 8902

Barry: Thank you for the informative post. No Hype, No maybe, just plain fact. Thanks again.

To: BARRY ALLEN who wrote (5940)	5/13/1998 4:52:00 PM
From: Steve D.	Respond to of 8902

Found this information on an ADVR search. Interesting for those who may not be aware of this. Clinical Results of RETICULOSE in Patients With AIDS NEW YORK, Dec. 10, 1996 -- Advanced Viral Research Corp (Nasdaq Bulletin Board: ADVR) today announced preliminary results of a clinical trial of its peptide nucleic acid drug RETICULOSE in patients with AIDS. The double-blind, randomized, placebo-controlled clinical trial is being conducted at The Queen Elizabeth Hospital, University of the West Indies School of Medicine, Barbados, by Henry Fraser, M.D., Timothy Roach, M.D., and Paul Levett, Ph.D. According to a written summary of the trial by Dr. Levett, forty-three patients never previously treated with HIV anti-retroviral therapy, were enrolled in the study. Twenty-one patients received RETICULOSE and twenty-two patients received placebo, administered daily, every other week, for a sixty-day period. Patients were observed for another sixty days following the conclusion of treatment. The polymerase chain reaction (PCR) assays for viral load were performed by LabCorp (Roche), and the CD4 counts were performed by SmithKline Beecham Clinical Laboratories. At the end of the sixty-day treatment period, the key results of this preliminary report were: -- A 37 percent increase in the mean CD4 positive T-cell lymphocytes counts in patients receiving RETICULOSE as compared with a 7 percent decrease in the control group that received placebo, and -- A 21 percent average decrease in HIV viral load, as measured by quantitative RNA PCR, in the RETICULOSE-treated patients, in contrast to a 33 percent increase in HIV viral load in the control group. At the end of the sixty-day observation period the mean HIV viral load of the treated group was less than half (42 percent) of the control group. Eighty-three percent of the patients who received RETICULOSE had a rise in blood hemoglobin and 61 percent had a rise in hemoglobin equal to or greater than one gram per deciliter (gm/dl). In contrast, 44 percent of patients who received placebo had a rise in blood hemoglobin during the study period, and in only 25 percent was the increase equal to or greater than 1 gm/dl. Clinically, 72 percent of patients who were given RETICULOSE maintained or increased their body weight. This occurred in only 30 percent of the placebo-treated patients. There was zero toxicity and no side effects were observed by physicians or reported by patients as a result of RETICULOSE therapy. "In view of the encouraging preliminary results of this clinical study in AIDS patients and the absence of any toxic side effects, we are eager to move forward to the next stage of this clinical trial with RETICULOSE," said Shalom Z. Hirschman, M.D., President and Chief Executive Officer of Advanced Viral Research Corp. "Drs. Fraser, Roach and Levett plan to submit the results for publication upon completion of the trial." ÿ ENMD:ÿ Quote ÿ\|ÿ Profile ÿ\|ÿResearch

To: BARRY ALLEN who wrote (5940)	5/13/1998 5:11:00 PM
From: OLD JAKE JUSTUS	Respond to of 8902

While not quiet accurate that is a good report. I recall the stock took a little longer to rise, than three days and it was around 11 cents when it first started. It stuck at 15 to 155 for a while and then it really got stuck at 3/8, and then she took off! I remember that we had a 32,000,000 and a 20,000,000+ single trading days. But there was never any publicity except for the abstract, (which I faxed to a lot of people in the United States, and overseas, but that was after the fact.) from JIM until the last week in August 1996. That's how I remember it. Many thanks!